Introduction {#Sec1}
============

Body weight (BW) loss is a common clinical manifestation in cancer patients, especially in those with advanced stage cancer. Cancer-related BW loss is usually associated with reduced physical function mainly owing to muscle wasting. Consequently, cancer-related BW loss can lead to worsening of patients' general condition and deterioration of performance status (PS) and quality of life (QOL) \[[@CR1], [@CR2]\]. Moreover, BW loss is a well-known prognostic factor in various malignant diseases and a prominent feature of cancer cachexia. Evans et al. defined cachexia as a metabolic syndrome associated with underlying illness, characterized by the loss of muscle with or without the loss of fat mass \[[@CR3]\]. Anorexia, inflammation, insulin resistance, hypogonadism, anemia, and others all form the complex web that underlies the development of cachexia. To maintain an acceptable condition and QOL during cancer care, it is necessary to address the clinical issues surrounding cancer cachexia. However, details of the onset mechanism of cancer cachexia remain unknown.

Lung cancer is a leading cause of cancer-related deaths in Japan. In 2012, 71,518 lung cancer patients died \[[@CR4]\]. In lung cancer patients, BW loss is a common occurrence and a matter of serious concern. Over the past 30 years, the frequency of BW loss in lung cancer patients has consistently exceeded that of other malignant diseases \[[@CR5], [@CR6]\]. To our knowledge, however, no large prospective study focusing on cancer-related BW loss has been reported in the field of lung cancer. In addition, BW loss has been known to deteriorate PS, QOL, and the prognosis of the patients, but it is unknown whether this is still applicable today when therapies for non-small cell lung cancer (NSCLC) have advanced significantly because of the development of new treatments such as molecularly targeted drugs. Therefore, we conducted a nationwide, multi-institutional, prospective, observational study to investigate the relationship between BW loss and related clinical parameters in patients with advanced non-small cell lung cancer (NSCLC). This study was conducted as the Japan Nutrition and QOL survey in patients with advanced NSCLC study (JNUQ-LC Study, TORG0912). It is hoped that this study will be helpful in further understanding cancer cachexia and optimizing the use of forthcoming anti-cachexia agents.

Patients and methods {#Sec2}
====================

Study design {#Sec3}
------------

The aim of this study was to observe the clinical course of advanced NSCLC focusing on BW and to elucidate the relationship between changes in BW and related clinical factors. The study was conducted at 75 facilities throughout Japan. All patients signed an informed consent. The study was approved by the institutional review boards of all participating facilities and was conducted in compliance with institutional review board regulations. This study is registered with University Hospital Medical Information Network-Clinical Trial Registry (UMIN-CTR) identification number: UMIN000003630.

Population {#Sec4}
----------

Patients with pathologically confirmed stage IV NSCLC, according to the 7th edition of the UICC TNM classification, were eligible for enrollment. Other eligibility criteria included age 20 years or older at the time of consent, being chemotherapy-naïve, and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0--2 (on a scale of 0--5, with 0 indicating that the patient is asymptomatic and higher numbers indicating increasing disability). Exclusion criteria included having surgery planned during the study period; inability to complete QOL questionnaires or perform a handgrip strength (HGS) test; and the presence of severe digestive diseases impeding oral ingestion, synchronous multiple primary cancers, uncontrolled severe diabetes mellitus, and uncontrolled psychiatric disorders.

Measurements of clinical parameters {#Sec5}
-----------------------------------

All clinical parameters were evaluated within 2 weeks before treatment as baseline data and every 4 weeks for 1 year after the start of treatment. Patients' BW was measured by weight scale (HBF-362, Omron Corporation, Kyoto, Japan) provided by the registration center. HGS was measured by grip dynamometer (Jamar Hydraulic Dynamometer, model \#MG-4005NC, Patterson Medical Holdings, Inc., Bolingbrook, IL) provided by the registration center. The HGS test was repeated three times each in the dominant and non-dominant hand, according to the procedure manual. QOL was scored by two screening questionnaires: the Japanese version of the M.D. Anderson Symptom Inventory (MDASI-J) \[[@CR7]\] and the QOL questionnaire for cancer patients treated with anticancer drugs (QOL-ACD) \[[@CR8]\]. The general condition of patients was evaluated using the Karnofksy Performance Scale (KPS). Biochemical assays, including white blood cell count and hemoglobin in peripheral blood, total protein, albumin, triglycerides, calcium, C-reactive protein (CRP), and insulin-like growth factor-1 (IGF-1) in serum, were also performed. Interleukin-6 (IL-6), acyl-ghrelin, des-acyl-ghrelin, leptin, and parathyroid hormone-related protein (PTHrP) were sampled and analyzed as optional parameters.

The modified Glasgow prognostic score (mGPS), an independent inflammation-based prognostic score of nutritional status in lung cancer patients, was tabulated. The mGPS was constructed using CRP and albumin as follows: patients with both an elevated CRP (≥10 mg/L) and low albumin (\<35 g/L) were allocated a score of 2; patients in whom only CRP was elevated (≥10 mg/L) were allocated a score of 1; and patients with a normal CRP were allocated a score of 0 \[[@CR9]\].

Statistical analysis {#Sec6}
--------------------

We hypothesized that cancer cachexia characterized by BW loss is tightly associated with QOL worsening. The relationship between various clinical parameters and BW change or QOL change from baseline was determined by structural equation modeling. McDonald's fit index was used to assess the fit of the structural equation model to data. This study was designed to have 80 % power to select the model using the goodness-of-fit test and McDonald's fit index \>0.95 with a type I error rate of 0.05 (two-sided) \[[@CR10]\]. Taking into account a dropout rate of 30 %, the sample size was determined to be 440.

To explore the change in BW loss, we compared the incidence of ≥5 % loss of BW in some time periods with patients' baseline BW using an incidence rate ratio (95 % confidence limit). The relationship between BW loss and other parameters was analyzed by simple and multiple linear regression analyses. The relative risk (95 % confidence interval \[CI\]) of BW loss (≥5 %) in patients experiencing progressive disease (PD) versus patients not experiencing PD, within 8 weeks after registration, and Fisher's exact test were calculated to evaluate whether early PD would affect BW loss. The association between specific therapy (treatment in the first 4 weeks after registration) and BW loss was evaluated in the same manner as early PD. To examine the relation between BW loss and cancer nutritional therapy, we compared the proportion of patients taking cancer nutritional therapy with BW loss levels and calculated the relative risk using a 95 % CI. The correlation between BW loss (and/or mGPS) and overall survival time was evaluated using standard survival analysis procedures. Estimated Kaplan-Meier plots and the log-rank test were applied to assess the statistical difference. Additionally, the Cox proportional hazards model was used to estimate the hazard ratios (95 % CI). Survival time was calculated from the date of registration to the date of death from any cause. Clinical factors associated with cancer cachexia were extracted through principal component analysis. We conducted this principal component analysis using the definition of cancer cachexia by Evans et al. for convenience because we needed to define it \[[@CR3]\]. The criteria included BW loss of at least 5 % over 6 months or less in the presence of an underlying illness plus three of the following: decreased muscle strength (≥5 % decrease in HGS for both the dominant and non-dominant hands), fatigue (≥grade 1 of CTCAE), anorexia (≥grade 1 of CTCAE), and abnormal biochemistry (CRP \> 5.0 mg/L, hemoglobin \<12 g/dL, and serum albumin \<3.2 g/dL). Low fat-free mass index was not included in these criteria because body composition was not investigated in the study. The relationship between these extracted factors and QOL deterioration was examined by a generalized estimating equation (GEE).

All missing values were not imputed. *p* \< 0.05 was considered statistically significant. All statistical analyses were performed using SAS software (version 9.2 or 9.3, SAS Institute).

Results {#Sec7}
=======

Patient demographics {#Sec8}
--------------------

Seventy-five facilities participated in the study. From February to July 2010, 466 patients were registered. Sixty patients were excluded due to the lack of BW data. The remaining 406 patients (280 male, 126 female) were evaluable and analyzed. Patient demographics are shown in Table [1](#Tab1){ref-type="table"}. The median age was 67 years (range, 33--87). The median BW was 56.5 kg (range, 31.9--92.7), and the mean body mass index was 21.79. The proportion of subjects with \>5 % BW loss observed within 6 months before registration in the study was 7.4 %; however, optional data were missing in 46.6 % of the registered subjects. Patients' PS ranged from 0 to 2: 0 (*n* = 159), 1 (*n* = 209), and 2 (*n* = 38). The mGPS was 0 (*n* = 373), 1 (*n* = 1), and 2 (*n* = 27). These data showed that the general status of most of the study subjects was favorable.Table 1Patient demographicsGenderMale280 (69.0 %)Female126 (31.0 %)AgeMean ± SD67.0 ± 10.1Median (range)67 (33--87)Height (cm)Mean ± SD161.5 ± 8.9Median (range)162.0 (134.6--185.0)Body weight (kg)Mean ± SD56.9 ± 10.1Median (range)56.5 (31.9--92.7)BMIMean ± SD21.79 ± 3.12Performance status0159 (39.2 %)1209 (51.5 %)238 (9.4 %)Body weight loss≤5 %187 (46.1 %) Within 6 months\>5 %30 (7.4 %) Before registrationUnmeasured189 (46.6 %)Modified Glasgow0373 (91.9 %)Prognostic score11 (0.2 %)227 (6.7 %)Unmeasured5 (1.2 %)*BMI* body mass index

Incidence of BW loss by observational period {#Sec9}
--------------------------------------------

The 52-week observational period was divided into four periods: first, 4 to 12 weeks; second, 16 to 24 weeks; third, 28 to 36 week; fourth, 40 to 52 weeks. The incidence rates of ≥5 % BW loss were similar in each period. The incidence rate ratios of ≥5 % BW loss (vs first) were second = 1.127, third = 1.059, and fourth = 1.158 (Table [2](#Tab2){ref-type="table"}).Table 2Incidence rate of weight loss (≥5 %) in observational periods in patients with advanced non-small cell lung cancerObservational periodsFirstSecondThirdFourth^a^Range of week4--1216--2428--3640--52Total number of observation1112865704713Weight loss (≥5 %), *n*276242185205Incidence rate0.2480.2800.2630.28895 % CL (lower, upper)(0.221, 0.279)(0.247, 0.317)(0.228, 0.304)(0.251, 0.330)Incidence rate ratio(vs first )11.1271.0591.15895 % CL (lower, upper)--(0.948, 1.340)(0.879, 1.275)(0.967, 1.388)*P* value--0.17400.54790.1108The 52-week observational period was divided into four periods: first, 4 to 12 weeks; second, 16 to 24 weeks; third, 28 to 36 weeks; fourth, 40 to 52 weeks*CL* confidence limit^a^Four observation periods in fourth period only; all others had three observation periods

Relationship between BW loss and QOL {#Sec10}
------------------------------------

Four hundred six patients were divided into four groups equally according to the percentage of BW loss from baseline: first quartile, BW loss ≤2.3 %; second quartile, BW loss 2.3 % ≤6.1 %; third quartile, BW loss 6.1 % ≤10.9 %; and fourth quartile, BW loss \>10.9 %. QOL was evaluated and scored using the MDASI-J questionnaire. Figure [1](#Fig1){ref-type="fig"} shows the distribution of a QOL score change from baseline in each group. Greater BW loss was associated with worsened QOL. The regression coefficient was −0.0291 (*P* = 0.0002), and the relationship between BW loss and QOL worsening was statistically significant. MDASI-J includes four subscales that reflect symptom severity, interference of daily activity, fatigue, and appetite loss. A similar analysis was performed on the relationship between BW loss and each subscale. Regression coefficients were −0.5268 in symptom severity (*P* = 0.0007), −0.3795 in interference of daily activity (*P* = 0.0003), −0.2596 in fatigue (*P* = 0.0077), and −0.2652 in appetite loss (*P* = 0.0038). BW loss was clearly correlated with the worsening of clinical factors in each subscale.Fig. 1Relationship between body weight loss and change of MDASI-J score. Increase in score change indicates worsening of quality of life (QOL). Four hundred six patients were divided into four groups equally according to percentage of body weight (BW) loss from baseline. First quartile includes patients with BW loss ≤2.3 %; second quartile, BW loss 2.3 % ≤6.1 %; third quartile, BW loss 6.1 % ≤10.9 %; and fourth quartile, BW loss \>10.9 %. QOL was evaluated and scored using MDASI-J questionnaire. Regression coefficient was −0.0291 (*P* = 0.0002) with linear regression analysis. MDASI-J, the Japanese version of the M.D. Anderson Symptom Inventory

Likewise, the relationship between BW loss and QOL evaluated by the QOL-ACD questionnaire was investigated. As shown in Supplementary Fig. [1](#MOESM1){ref-type="media"}, a significant relationship was observed with a regression coefficient of 0.0631 (*P* \< 0.0001). Regression coefficients in four subscales were 0.1234 in daily activity (*P* \< 0.0001), 0.2238 in physical condition (*P* \< 0.0001), 0.1700 in psychological condition (*P* = 0.0003), and 0.1509 in sociality (*P* = 0.0017). In the face scale of QOL-ACD, used to evaluate general QOL, a strong relationship was observed with a regression coefficient of 0.8457 (*P* \< 0.0001).

Relationship between BW loss and performance status {#Sec11}
---------------------------------------------------

The distribution of KPS change in each group is shown in Supplementary Fig. [2](#MOESM2){ref-type="media"}. The regression coefficient was 0.0363 (*P* \< 0.0001). Greater BW loss correlated with worse performance status.

Relationship between BW loss and handgrip strength {#Sec12}
--------------------------------------------------

The distribution of HGS change in the non-dominant hand in each BW loss group is shown in Supplementary Fig. [3](#MOESM3){ref-type="media"}. The regression coefficient was 0.4363 (*P* \< 0.0001) in the non-dominant hand and 0.3915 (*P* \< 0.0001) in the dominant hand. Patients with more BW loss showed greater decreases in HGS, especially in the non-dominant hand. Similarly, the relationship between HGS change and QOL score change or KPS change was analyzed. The decrease in HGS in the non-dominant hand was clearly related to significant worsening of QOL or KPS (data not shown).

Relationship between BW loss and biochemical parameters {#Sec13}
-------------------------------------------------------

BW loss correlated with several biochemical parameters. The regression coefficients were 0.1312 in lymphocyte count (*P* \< 0.0001), 0.7364 in hemoglobin (*P* \< 0.0001), 2.2637 in serum albumin (*P* \< 0.0001), 4.6048 in serum triglycerides (*P* = 0.0011), −1.2260 in CRP (*P* = 0.0016), 0.0218 in IGF-1 (*P* = 0.0023), and 10.8947 in leptin (*P* = 0.00358). There was no correlation between BW loss and other parameters (IL-6, acyl-ghrelin, des-acyl-ghrelin, and PTHrP), partly owing to the small sample number.

Investigation of factors possibly affecting BW loss {#Sec14}
---------------------------------------------------

Factors possibly associated with BW loss were investigated. These included PD, anticancer therapy, and nutritional therapy (intake of food high in nutrition and high-calorie infusion). BW loss occurred more frequently in patients with PD than in patients with non-PD (relative risk, 1.30; 95 % CI, 1.08--1.58; *P* = 0.0254). No difference was observed on the influence of BW loss among therapies (platinum-based, non-platinum-based, or molecular targeted therapy) or no therapy. Differences were observed between the molecular-targeted therapy group and the treatment-naïve group. The impact of nutritional therapy on BW loss was not confirmed; however, the number of patients who used the therapy was too small for evaluation. These data suggest that PD may affect the onset of BW loss.

Overall survival {#Sec15}
----------------

The median overall survival (OS) in all patients (*N* = 384) was 1.15 years, with a median follow-up of 1.06 years. The comparison of OS in four quartiles by BW loss revealed statistically significant shorter OS as BW loss increased by the log-rank test (first vs third: *P* = 0.0011; first vs fourth: *P* \< 0.0001) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Overall survival curves according to the percentage of body weight lossThe overall survival curve was drawn using the Kaplan-Meier method: first quartile, body weight (BW) loss ≤2.3 %; second quartile, BW loss 2.3 % ≤6.1 %; third quartile, BW loss 6.1 % ≤10.9 %; and fourth quartile, BW loss \>10.9 %. *Q* quartile, *HR* hazard ratio

We also analyzed the effect of BW loss before enrollment. Approximately 7.4 % of all patients experienced BW loss of 5 % or more 6 months before registration; however, there was no statistical difference in overall survival time between patients with or without prior BW loss (*P* = 0.1524). The OS was analyzed using Cox proportional hazards model with BW loss and mGPS as covariates. Greater BW loss or a higher mGPS score (score 0 vs 1 and 2) correlated with a shorter OS. Both BW loss and mGPS were considered independent prognostic factors (Supplementary Table [1](#MOESM1){ref-type="media"}).

The principal component analysis of cancer cachexia {#Sec16}
---------------------------------------------------

We listed various factors representing cancer cachexia and investigated their strength in relation to cachexia by analyzing the core components (Table [3](#Tab3){ref-type="table"}). Four factors were found to have a high degree of impact in cancer cachexia: BW loss, decrease in HGS, anorexia, and fatigue. The degree of impact of these factors was as follows: BW loss, 0.654; decrease in HGS, 0.592; anorexia, 0.825; and fatigue, 0.749. Statistical analysis of time-course data using GEE was performed to explore the degree of progression of cancer cachexia that contributed to changes in QOL. Progression of these four factors contributed strongly to the deterioration of QOL (*P* \< 0.01).Table 3Principal component analysis of cancer cachexiaSymptoms comprising the factor^a^Degree of impact on the factors^b^Body weight loss0.654Decrease in handgrip strength0.592Fluid retention0.178Gastrointestinal tract disturbance0.420Anorexia0.825Motor function disorder0.124Pain0.525Fatigue0.749Respiratory embarrassment0.116Steroid administration0.002Parenteral hyperalimentation0.458^a^Evaluated at date of weeks closest to when the maximum change in quality of life was observed^b^Figures closer to 1.000 indicate a stronger impact

Discussion {#Sec17}
==========

This prospective study demonstrated that BW loss in advanced NSCLC patients correlated with worsening of QOL and KPS and a decrease in HGS. QOL was evaluated using two questionnaires: MDASI-J and QOL-ACD. MDASI-J was used to assess multiple symptoms experienced by cancer patients and their interference with patients' activities of daily living. The QOL-ACD focuses on patients treated with anticancer drugs and evaluates not only their physical status but also their psychological status and ability to engage in social activities. Both QOL evaluation methods demonstrated that BW loss was strongly associated with worsening of QOL. Biochemical assays suggest that systemic inflammation, malnutrition, and anemia are cofactors in involuntary weight loss. These poor general conditions contribute markedly to patients' decreased QOL, as reported previously. Furthermore, the greater the BW loss, the shorter the OS became; BW loss is a prognostic factor, independent of mGPS. Thus, BW loss in cancer patients must be carefully monitored throughout the clinical course of treatment.

Fearon et al. recently participated in a formal consensus process and proposed a new definition of cachexia \[[@CR11]\]. The international consensus defined cancer cachexia as a multifactorial syndrome identified by the "ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment." The diagnostic criterion agreed upon for cachexia was weight loss greater than 5 % or weight loss greater than 2 % in individuals already showing depletion according to current bodyweight and height (BMI \<20 kg/m^2^ or sarcopenia) \[[@CR11]\]. It is noteworthy that this definition took into consideration the possibility of having a patient who was relatively slim before developing cancer. Since body size between Caucasians and Asians varies (Asians being generally slimmer and smaller), the criterion should be validated before it is applied to Asian patients.

From our observations during this study, we found that BW loss occurred early after the initiation of cancer treatment and was sustained consistently throughout the 52-week observational period. The influence of anticancer therapy and nutritional therapy on BW loss was limited; however, the onset of BW loss pointed to PD.

These results suggest the importance of recognizing BW loss in advanced NSCLC patients and intervening quickly and appropriately. The importance of initiating treatment for BW loss early is supported by a report of early palliative care for NSCLC patients, which resulted in longer patient survival \[[@CR12], [@CR13]\]. Fearon et al. categorized cancer cachexia into three stages: precachexia, cachexia, and refractory cachexia \[[@CR11]\]. Because refractory cachexia is clinically unresponsive to anticancer therapy, it is important to recognize cachexia as soon as possible by monitoring BW loss, at least before it progresses to the refractory stage. In addition, we should pay more attention to BW loss because our findings have shown that the disadvantages associated with BW loss are still the same despite the progress in NSCLC therapies. However, wider awareness of the importance of BW loss through this study could improve care because BW can be easily measured anywhere.

As reported previously, BW loss may be associated with incompletion of chemotherapy courses and treatment-related toxicities \[[@CR14], [@CR15]\]. In this study, we also analyzed the effect of BW loss prior to enrollment; however, there was no statistical difference in OS time between patients with or without prior BW loss. Although this interpretation is limited because of the small sample size, BW loss that occurred before or after systemic chemotherapy seemed to affect survival differently.

We also focused on other symptoms accompanied by BW loss and identified them by analyzing the principal components (Table [3](#Tab3){ref-type="table"}). Our observation confirmed that cancer cachexia is characterized by anorexia, fatigue, and loss of muscle strength, as well as BW loss. These four factors are linked tightly to each other and are considered core factors in cachexia. Progression of these factors was strongly associated with worsening of QOL. This study result demonstrates that BW loss leads to decrease in clinical parameters such as QOL, KPS, and HGS. We found that the BW loss is one of the core factors of cancer cachexia, which is consistent with the criteria proposed by Fearon or Evans that implicate BW loss as a key factor in cancer cachexia \[[@CR3], [@CR11]\].

In patients treated with systemic chemotherapy, however, it is difficult to distinguish toxicities associated with cancer chemotherapy from cachexia-related symptoms. Since patients were treated with chemotherapy during this study, BW loss or QOL worsening was due in part to the adverse effects of treatment and is thus a limitation of this study. When symptoms possibly associated with systemic chemotherapy, such as anorexia and/or fatigue, last longer than expected, cachexia should be suspected.

Based on the results of this study, we identified that there were correlations between BW loss and the deterioration of other clinical factors such as QOL. However, we did not quantify how BW loss contributed to the changes in these factors. If these quantifications could be identified, the prophylaxis against BW loss by some treatments can contribute the deterioration of such factors. A GEE or a repeated measure ANOVA may be appropriate to solve those problems.

Cachexia is an important clinical target. Until recently, there have been attempts at therapeutic approaches to cachexia through nutritional support, rehabilitation/exercise \[[@CR16]\], corticosteroid administration, and herbal medicine for cancer patients, but the effectiveness of these treatments has been limited. The development of anti-cachexia drugs, such as enobosarm and anamorelin, however, offers promise. These drugs have been shown to increase total lean body mass and/or improve anorexia/cachexia symptoms \[[@CR17], [@CR18]\].

Continued clinical research of cachexia is essential for improving patients' tolerance to cancer therapies and QOL. The goal should be to develop preventive measures and treatment for cachexia based on a more complete understanding of the underlying pathophysiology of the syndrome.
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Relationship between BW loss and change of QOL-ACD score (PPTX 102 kb) A total of 406 patients were divided into four groups (see also Fig. [1](#Fig1){ref-type="fig"}). Quality of life (QOL) was evaluated and scored using QOL-ACD questionnaire. An increase in score indicates an improvement in QOL. Regression coefficient (0.0631; *P* \< 0.0001) was determined by linear regression analysis. QOL-ACD, the QOL questionnaire for cancer patients treated with anticancer drugs

###### 

Relationship between body weight loss and change of KPS A total of 406 patients were divided into four groups (see also Fig. [1](#Fig1){ref-type="fig"}). An increase in KPS indicates an improvement in quality of life. Regression coefficient (0.0363; *P* \< 0.0001) was determined by linear regression analysis. KPS, the Karnofksy Performance Scale (PPTX 99 kb)

###### 

The relationship between body weight loss and handgrip strength in the non-dominant hand A total of 308 patients were divided into four groups (see also Fig. [1](#Fig1){ref-type="fig"}). Regression coefficient was 0.4363 (*P* \< 0.0001) determined by linear regression analysis (PPTX 101 kb)
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